ArticleBiomarker research2021
Inflammation-related genes S100s, RNASE3, and CYBB and risk of leukemic transformation in patients with myelodysplastic syndrome with myelofibrosis.
Open access · goldAbstract readLetter
In one paragraph
Article in Biomarker research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Inflammation as a central driver in AML pathogenesis and therapy resistance.Science China. Life sciences · 2026Review
- Identification of common genetic factors and immune-related pathways associating more than two autoimmune disorders: implications on risk, diagnosis, and treatment.Genomics & informatics · 2024Article
- Bioinformatics analysis and prediction of Alzheimer's disease and alcohol dependence based on Ferroptosis-related genes.Frontiers in aging neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Minghua Hong *Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Junqing Wu *Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Lifeng MaCenter for Stem Cell and Regenerative Medicine, Stem Cell Institute, School of Medicine, Zhejiang University, 310058, Hangzhou, China.
Xiaoping HanCenter for Stem Cell and Regenerative Medicine, Stem Cell Institute, School of Medicine, Zhejiang University, 310058, Hangzhou, China.
Ting LuBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Zhaoming WangPathology Department, the First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China.
Jing ZhaoPathology Department, the First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China.
Lizhen LiuBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Huarui FuBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Weijia HuangBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Weiyan ZhengBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Jingsong HeBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Guoqing WeiBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Huanping WangBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Zhimei ChenBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
He HuangBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Zhen CaiBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China.
Guoji Guo *Center for Stem Cell and Regenerative Medicine, Stem Cell Institute, School of Medicine, Zhejiang University, 310058, Hangzhou, China.
Jie Sun *Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 310003, Hangzhou, China. jsun1492@zju.edu.cn.
Zhejiang University · CNFirst Affiliated Hospital Zhejiang University · CN
Funding
National Natural Science Foundation of China 82070200Natural Science Foundation of Zhejiang Province (CN) LQ20H160025
Abstract
Myelodysplastic syndrome with myelofibrosis (MDS-MF) has been associated with an inferior prognosis compared with MDS without MF. However, MDS-MF is not listed independently as a subtype of MDS, and its clinical and genetic characteristics remain poorly understood. We retrospectively compared 53 patients with MDS-MF (44 MF grade 1/MF
Indexed as
InflammationLeukemic transformationMyelodysplastic syndromeMyelofibrosisSingle-cell sequence
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.